{"analyses":[{"ciLowerLimit":"161.41","ciNumSides":"TWO_SIDED","ciPctValue":"90","ciUpperLimit":"289.56","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"Ratio of adjusted geometric means","paramValue":"216.19"},{"ciLowerLimit":"141.09","ciNumSides":"TWO_SIDED","ciPctValue":"90","ciUpperLimit":"868.23","groupIds":["OG002","OG003"],"nonInferiorityType":"SUPERIORITY","paramType":"Ratio of adjusted geometric means","paramValue":"350.00"},{"ciLowerLimit":"263.22","ciNumSides":"TWO_SIDED","ciPctValue":"90","ciUpperLimit":"507.31","groupIds":["OG004","OG005"],"nonInferiorityType":"SUPERIORITY","paramType":"Ratio of adjusted geometric means","paramValue":"365.43"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"27","value":"41.77"},{"groupId":"OG001","spread":"33","value":"90.78"},{"groupId":"OG002","spread":"38","value":"37.71"},{"groupId":"OG003","spread":"31","value":"151.45"},{"groupId":"OG004","spread":"36","value":"32.10"},{"groupId":"OG005","spread":"87","value":"112.78"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"14"},{"groupId":"OG005","value":"8"}],"units":"Participants"}],"description":"AUCinf = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-inf).","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.","id":"OG000","title":"Low Dose Escalation Cohort: Crizotinib 100 mg QD (Midazolam Alone)"},{"description":"Participants received Crizotinib 100 mg capsule or tablet orally QD along with single 2 mg oral dose of Midazolam on Cycle 2 Day 1.","id":"OG001","title":"Low Dose Escalation Cohort: Crizotinib 100 mg QD + Midazolam"},{"description":"Participants who did not receive Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet BID on Day -7, received single 2 mg oral dose of Midazolam on Day -7.","id":"OG002","title":"Low Dose Escalation Cohort: Crizotinib 300 mg BID (Midazolam Alone)"},{"description":"Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID along with 2 mg oral dose of Midazolam on Cycle 2 Day 1.","id":"OG003","title":"Low Dose Escalation Cohort: Crizotinib 300 mg BID + Midazolam"},{"description":"Participants who did not receive Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet on Day -7, received single 2 mg oral dose of Midazolam on Day -7","id":"OG004","title":"RP2D Cohort: Crizotinib 250 mg (Midazolam Alone)"},{"description":"Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) BID along with single 2 mg oral dose of Midazolam on Cycle 2 Day 1.","id":"OG005","title":"RP2D Cohort: Crizotinib 250 mg +Midazolam"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"The PK concentration population of midazolam included all participants treated with midazolam (including Day -7 dose) who have at least 1 concentration of midazolam.","reportingStatus":"POSTED","timeFrame":"pre-dose, 0.5, 1, 2, 4, 6, 8, 9, and 24 hours post dose on Day -7 (midazolam alone arm), pre-dose, 0.5, 1, 2, 4, 6, 8, 9, and 24 hours post dose on Cycle 2 Day 1 (midazolam with crizotinib arm)","title":"Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of Midazolam When Taken Alone or Taken With Crizotinib","type":"PRIMARY","unitOfMeasure":"nanogram*hour per milliliter"}